Issued: Friday 25 October 2013, London UK GlaxoSmithKline plc (GSK) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an additional indication for …
London, UK – 25 October 2013: ViiV Healthcare today announced the submission of a regulatory application in Europe for its investigational single-tablet regimen (STR) combining dolutegravir (DTG), abacavir (ABC) and lamivudine (3TC) for the treatment of …
Issued: Friday 25 October 2013, London UK São Paulo, Brazil GSK today announced it has formed a new collaboration with the São Paulo Research Foundation (FAPESP) to create a new Centre of Excellence for Sustainable Chemistry in Brazil. The agreement was …
Wednesday 23 October GSK announces Q3 core EPS growth of16% and dividend of 19p Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies Pharma Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by EMAP -9%, …
Issued: Wednesday 23 October 2013, London UK GlaxoSmithKline plc (LSE:GSK) today announced the submission of a New Drug Application (NDA) in the US for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the …
London, UK – 22 October 2013 ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR) combining dolutegravir, abacavir and lamivudine for the treatment of people …
Issued: Friday 18 October 2013, London UK GlaxoSmithKline plc [LSE/NYSE: GSK] and Genmab A/S [OMX: GEN] announced today the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for the use of …
EMBARGOED UNTIL TUESDAY 8 OCTOBER 2013, 00.01hrs BST, 01.01hrs SAST - Malaria is a significant public health burden, claiming 660,000 lives a year - mostly children in sub-Saharan Africa -Data support plan to submit regulatory application in 2014 …
Issued: Friday 4 October 2013, London UK GlaxoSmithKline plc and Genmab A/S [OMX: GEN] announced today the submission of a variation to the Marketing Authorisation to the European Medicines Agency (EMA) for the use of Arzerra (ofatumumab) in combination …
Issued: Monday 30 September 2013, London UK – LSE Announcement GlaxoSmithKline (LSE:GSK) today announced it has reached agreement to sell its thrombosis brands, Arixtra® and Fraxiparine®, and the Notre-Dame de Bondeville (NDB) manufacturing site to The …
Issued: Friday 27 September 2013, London, UK New York, US GlaxoSmithKline (GSK) and Barclays have formed a new partnership which aims to increase access to affordable healthcare and medicines for people in Zambia, while helping to create improved economic …
Issued: Tuesday 24 September 2013, London UK GlaxoSmithKline plc announced today that the European Commission has granted an additional indication for Revolade™ (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with …
Issued: Friday 20 September 2013, London UK, Leiden, Netherlands GlaxoSmithKline (GSK) and Prosensa today announced that GSK’s Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular …
Issued: Friday 20 September 2013, London UK and South San Francisco, CA, USA GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ …
Issued: Thursday 19 September 2013, London UK – LSE Announcement GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has …
Issued: Thursday 19 September 2013, London UK GlaxoSmithKline (GSK) plc today announced a new four year contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services (HHS), for the …
Issued: Monday 16 September 2013, London UK – LSE announcement GlaxoSmithKline plc (LSE:GSK) today announced that the US Food and Drug Administration (FDA) has granted Priority Review designation to its supplemental New Drug Applications (sNDAs) for …
Issued: 13 September 2013, London UK GlaxoSmithKline plc (LSE:GSK) and Genmab A/S (OMX: GEN) announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Arzerra® (ofatumumab) in combination with …
Issued: September 13, 2013, Philadelphia, PA GlaxoSmithKline confirmed today that the Court of Appeals for the Federal Circuit has ruled against Pronova Biopharma Norge AS in its patent litigation regarding Lovaza® (omega-3-acid ethyl esters). Reversing a …
Denver, 12 September 2013 ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1 ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study. …
